Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immuron Limited (AU:IMC)
ASX:IMC
Holding AU:IMC?
Track your performance easily
IMC Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.07 - AU$0.17
Previous CloseAU$0.08
Volume1.35K
Average Volume (3M)260.01K
Market Cap
AU$17.19M
Enterprise ValueAU$26.14K
Total Cash (Recent Filing)AU$17.16M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Feb 26, 2025EPS Estimate
AU$0Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding227,798,346
10 Day Avg. Volume61,095
30 Day Avg. Volume260,008
Standard Deviation0.34
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)0.83
Price to Sales (P/S)16.10
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-6.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Immuron Limited News
PremiumCompany Announcements
Immuron Limited Showcases Promising Biopharmaceutical Innovations
PremiumCompany Announcements
Immuron Limited Secures Approval on Key AGM ResolutionsPremiumCompany Announcements
Immuron Limited Sees Record Sales and Positive Trial Developments
PremiumCompany Announcements
Immuron Limited Director’s Option Expiry UpdatePremiumCompany Announcements
Immuron Limited Issues New Unquoted Performance RightsPremiumCompany Announcements
Immuron Limited Schedules 2024 Annual General Meeting
PremiumCompany Announcements
Immuron’s Innovative Antibody Solutions Highlighted at Healthcare Conference
PremiumCompany Announcements
Immuron Limited Showcases Innovations at Healthcare ConferenceOptions Prices
Currently, No data available
---
Ownership Overview
IMC FAQ
What was Immuron Limited’s price range in the past 12 months?
Immuron Limited lowest share price was AU$0.07 and its highest was AU$0.17 in the past 12 months.
What is Immuron Limited’s market cap?
Currently, no data Available
When is Immuron Limited’s upcoming earnings report date?
Immuron Limited’s upcoming earnings report date is Feb 26, 2025 which is in 95 days.
How were Immuron Limited’s earnings last quarter?
Immuron Limited released its earnings results on Aug 30, 2024. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Immuron Limited overvalued?
According to Wall Street analysts Immuron Limited’s price is currently Overvalued.
Does Immuron Limited pay dividends?
Immuron Limited does not currently pay dividends.
What is Immuron Limited’s EPS estimate?
Immuron Limited’s EPS estimate is AU$0.
How many shares outstanding does Immuron Limited have?
Immuron Limited has 229,145,430 shares outstanding.
What happened to Immuron Limited’s price movement after its last earnings report?
Immuron Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -1.961%.
Which hedge fund is a major shareholder of Immuron Limited?
Currently, no hedge funds are holding shares in AU:IMC
---
Immuron Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IMC Sentiment 94%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.30%
12-Months-Change
Fundamentals
Return on Equity
-42.92%
Trailing 12-Months
Asset Growth
-29.28%
Trailing 12-Months
Company Description
Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
---
Technical Analysis
---